A cell-free regenerative approach. Tiny signaling particles called exosomes are being studied for their ability to support your body's own repair processes, with minimal downtime.
Exosomes are tiny particles your cells release to send messages to other cells. They are 30 to 150 nanometers across and carry no living cells. Instead, they act like small packages filled with proteins, fats, and genetic signals. When they reach damaged tissue, they deliver signals that may encourage repair.
Research suggests exosomes from stem cells may do four key things. They deliver signaling molecules into cells. They may help calm the immune system when it is overreacting. They may help cells survive and grow. And they may support the growth of new blood vessels, which brings more oxygen to injured areas. Together, these effects are why researchers are studying exosomes as more than symptom relief.
One major advantage of exosomes is consistency. They can be made in large batches, measured into exact doses, and stored for a long time without losing their effectiveness. This makes each treatment more predictable than therapies that use living cells, which can vary from donor to donor.
Both approaches use the body's natural ability to heal, but they work differently in terms of method, invasiveness, and how fast results appear.
Exosomes from stem cells are being studied for their effects on joint inflammation and cartilage health. Some patients with knee, hip, and shoulder problems report less pain and better movement, though results vary and are not guaranteed.
Researchers are studying whether exosomes may help regulate the immune system rather than simply suppress it. Conditions under investigation include rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, and inflammatory bowel disease. These uses are investigational and not FDA-approved.
Exosomes are being studied for their calming effect on the immune system, which is why they are being explored for whole-body inflammation, chronic pain, and metabolic conditions where low-level inflammation persists.
Exosomes are being studied for skin quality. Some patients report improvements in texture, firmness, and visible signs of aging, and exosomes are being explored for fine lines, sun damage, rosacea, acne, and dark spots left from past breakouts.
A 30 to 60 minute outpatient visit. No cell harvesting needed. Most patients return to normal activity the same day.
The treating provider reviews your health history and goals to design your treatment plan. Before your visit, drink plenty of water, avoid blood thinners and alcohol for 24 hours, and eat a light meal beforehand.
Depending on your condition, exosomes are given by direct injection into the target area or through an IV. We use fine needles and guide them precisely. Most patients feel little to no discomfort.
Some patients notice mild redness, swelling, or tenderness at the injection site. This usually clears up within 24 to 48 hours. Avoid sun exposure and intense exercise the first day. There is no significant downtime.
Most conditions respond best to a series of sessions. The treating provider will recommend follow-up treatments every 3 to 6 months to keep the healing response strong and maintain your results long-term.
Not sure whether this applies to your case? Candidacy is determined by medical review of your history and imaging, not by a form. The consultation is complimentary.
See If You QualifySome patients notice changes sooner with exosome therapy than with stem cell therapy, possibly because the signaling molecules are active right away rather than depending on living cells to settle in.
Skin patients often notice better hydration and a brighter appearance. For other conditions, inflammation levels start to decrease during this period.
Patients who respond often report the most noticeable changes in this window, such as less pain, easier movement, or visible skin improvement. Results vary.
Patients who respond usually have a clearer sense of their results by this point. Stem cell therapy often takes longer, with the most change usually reported at 3 to 6 months.
Some patients report continued gradual changes, such as firmer skin or steadier joint comfort. Your physician will assess your progress at follow-up.
Exosome therapy is investigational and is not approved by the U.S. Food and Drug Administration. The evidence base is considerably thinner than for stem cell therapy, and much of the published human research concerns hair and skin rather than joints. That distinction matters if you are considering it for a joint.
A 2025 trial in the Journal of Translational Medicine injected exosomes derived from umbilical cord mesenchymal stem cells into the knees of 41 patients across 45 joints with mild to moderate osteoarthritis, at three dose levels, with nine months of follow-up. The authors reported no adverse consequences and no significant difference in safety measures between dose groups. The highest-dose group showed improvement in WOMAC pain, stiffness and daily function scores.
The trial had no control group. The authors note this was due to ethical review, but the consequence is that the improvement cannot be separated from placebo effect or the natural course of the condition. They describe their own findings as showing "a certain degree of effectiveness" and call it the first clinical application of this treatment. The sample was small, severe osteoarthritis was excluded, and most other exosome research in joints remains preclinical or in animal models.
What that means in practice: early safety signals are reasonable, effectiveness is not established, and the honest summary is that this is a newer and less studied option than stem cell therapy rather than a more advanced one. Whether it suits your case is a decision for a physician who has reviewed your history and imaging.
Source: Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis: from preclinical to clinical research, Journal of Translational Medicine, 2025.
Exosomes are cell-free nano-vesicles that carry growth factors, signaling molecules, and proteins. They facilitate cell-to-cell communication and can support tissue repair and immune modulation without introducing living cells into the body.
Exosome therapy is a cell-free approach: it delivers regenerative signaling molecules without transplanting living cells. Some patients who respond notice changes sooner than with cell therapy, often within 4 to 8 weeks, and it may be appropriate for patients who prefer a non-cellular protocol. Results vary.
Exosome therapy is evaluated for joint pain, tissue repair support, immune modulation, and systemic inflammation. The treating provider determines whether exosomes are the right fit based on your specific condition and medical history.
Because exosomes are cell-free, there is no risk of cell rejection. All products are sourced from GMP-certified facilities with rigorous testing for sterility and potency. As with any medical procedure, a full evaluation is required before treatment.
Many patients notice changes within 4 to 8 weeks. Results vary depending on the condition being treated, its severity, and individual response. The treating provider will set realistic expectations during your consultation.
Connect with our coordination team to explore whether exosome therapy may be available for your condition and goals through an independent provider.
CHECK IF YOU QUALIFY →